The emerging stimulant drug of abuse (3,4)-methylenedioxypyrovalerone
[(R,S)-MDPV] is self-administered as a racemic mixture by intranasal,
iv, oral, and smoking routes. The individual enantiomers are known to have widely
different pharmacological effects, with (S)-MDPV showing much greater
potency than (R)-MDPV in pharmacological testing. The goal of these
studies was to develop and validate an analytical method for quantitation of
(R)-MDPV, (S)-MDPV and (R,S)-MDPV in
small volumes of rat serum using a chiral separation column and liquid chromatography-mass
spectrometry. The method was validated for selectivity, precision, accuracy, recovery,
sensitivity, and reproducibility. The method was also used to determine the enantiomeric
stability of the individual enantiomers during sample cleanup and analysis. The linear
dynamic range of the calibration curve was 1 – 1000 ng/ml for each enantiomer.
Concentration values for the lower limit of quantitation (1 ng/ml) were within 30%
of their nominal value, but all other calibration standards were <20% of
their nominal value. With proper storage and handling of samples, the two MDPV enantiomers
were shown to remain stable in rat serum without any apparent racemization during the time
needed for analysis. Finally, the ruggedness of the method was demonstrated with diluted
and undiluted serum samples collected from Sprague Dawley rats in a preliminary
pharmacokinetic study at 3 mg/kg of (R,S)-MDPV. In summary, the assay
used a simple sample preparation method, reversed-phase chiral chromatography, and tandem
mass spectrometry to achieve accurate and selective determinations of MDPV enantiomer
concentrations in small volumes of serum.